Morningstar

Damien Conover, CFA

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

More From Damien Conover

The drugmaker offers investors robust growth and an attractive dividend, notes Morningstar's analyst.
Damien Conover, CFA

Morningstar's analyst says there's much more to Pfizer's products than COVID-19 vaccines and treatments.
Damien Conover, CFA

The surprise breakup will allow both new companies to operate with more focus and agility. We don't see this impacting our fair value estimate.
Damien Conover, CFA

We have raised our fair value estimate based on the company's strong performance.
Damien Conover, CFA

Drug and biotech industries pricing in the risk of policy changes in the U.S., but we don't think there will be a big regulatory impact.
Damien Conover, CFA

More About Damien Conover

Damien Conover, CFA, is director of equity research, North America, for Morningstar*.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center